Eleva Capital SAS Takes $1.29 Million Position in Eli Lilly and Company $LLY

Eleva Capital SAS acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 1,651 shares of the company’s stock, valued at approximately $1,287,000. Eli Lilly and Company comprises approximately 0.3% of Eleva Capital SAS’s investment portfolio, making the stock its 19th largest position.

Several other hedge funds have also recently made changes to their positions in LLY. Wealth Preservation Advisors LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at approximately $27,000. Blume Capital Management Inc. increased its holdings in Eli Lilly and Company by 46.7% during the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the second quarter valued at approximately $35,000. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, TD Capital Management LLC increased its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

LLY opened at $862.96 on Friday. The firm has a market cap of $816.76 billion, a P/E ratio of 56.40, a PEG ratio of 1.21 and a beta of 0.47. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a 50 day simple moving average of $780.74 and a two-hundred day simple moving average of $771.71. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Insider Activity

In related news, Director Jamere Jackson bought 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director J Erik Fyrwald bought 1,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 in the last quarter. Company insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on LLY. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. HSBC upped their target price on shares of Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Guggenheim reiterated a “buy” rating and issued a $948.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Finally, DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $940.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.